PDCD1 and non-small cell lung carcinoma: Six phase 3 RCTs that investigated a PD-1 inhibitor plus chemotherapy versus chemotherapy as first-line therapy for advanced squamous (SQ) NSCLC were identified: CameL-Sq (25), CheckMate 227 Part 2 (20), EMPOWER Lung-3 (21), KEYNOTE-407 (26), CHOICE-01 (23), and RATIONALE 307 (27) (Table 4; Figure 6).